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Abstract
Objective: We aimed to understand the attitudes, preferences and acceptance of oral and parenteral PrEP among men who
have sex with men (MSM) in Thailand.
Background: Pre-exposure prophylaxis (PrEP), the use of antiretrovirals to prevent HIV acquisition, has shown promising
results in recent trials. To assess the potential impact of this new HIV prevention method, in addition to efficacy data, we
need to understand which psychosocial factors are likely to determine its uptake among members of potential user groups.
Methods and Findings: Surveys of willingness to use PrEP products were administered to MSM. Spearman’s rank tests were
used to uncover associations between questionnaire items. Mann-Whitney tests were performed to ascertain differences
between groups. Conjoint analysis was used to examine the attitudes and preferences of MSM towards PrEP attributes.
Most participants were willing to consider taking PrEP (39.2% ‘‘yes, definitely’’ and 49.2% ‘‘yes, probably’’) and perceived
PrEP as giving them new possibilities in their lives (38.5% ‘‘a lot of hope’’ and 55.8% ‘‘some hope’’), even after being
instructed of potential side effects and costs. HIV testing was considered the most important attribute and a daily pill and
longer lasting injection in the arm were the preferred routes of administration.
Conclusions: Despite its multiple challenges, MSM in Thailand would be willing to take PrEP, even if they had to experience
inconvenience and expense. If PrEP were to be implemented in Thailand, our findings show that its uptake could be
considerable.
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Introduction
In the 1990s, Thailand achieved a significant reduction in
overall HIV incidence by enforcing condom use in brothels and
ensuring wide access to HIV prevention information through the
mass media, schools and the workplace [1,2,3,4]. Despite these
efforts, certain populations remain disproportionally affected by
the epidemic, notably men who have sex with men (MSM). Recent
surveys show that one in four MSM is infected with HIV in
Bangkok [5,6], and one in eight in Chiang Mai [7]. Improving and
expanding existent HIV prevention programs, and introducing
new initiatives that take into consideration the needs of this
population, are urgently needed to address this health inequality.
Antiretroviral-based prevention, a strategy to prevent HIV
transmission (treatment as prevention or TasP) or acquisition
(preexposure prophylaxis or PrEP), could be part of the solution.
Early treatment of those infected with HIV reduced the risk of
transmission to uninfected partners of heterosexual couples by
96% in the HPTN-052 trial [8]. TasP, however, has yet to be
tested among MSM. PrEP, on the other hand, reduced the risk of
HIV infection by an average of 44% (73% among high adherers)
in HIV negative MSM and transgender women who participated
in iPrEx, a clinical trial testing a daily oral dose of the
antiretroviral drug Truvada [9].
Following the iPrEx results, the U.S. Food and Drug
Administration recently approved the use of TruvadaH for
prevention purposes [10]. Clinical guidance for its use among
MSM has been released in the U.S. by the Centers for Disease
Control and Prevention [11] _ENREF_16and South Africa [12],
and the World Health Organization has issued guidance on the
use of PrEP for MSM in the context of demonstration projects
[13].
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As demonstration projects are beginning to take place in
preparation for an eventual PrEP rollout [14,15], multi-disciplin-
ary research aimed at identifying where existing and new HIV
prevention methods may fit best within a combination prevention
package is of critical importance. An aspect which deserves
consideration is users’ acceptance of the prevention methods on
offer [16,17,18].
In the case of PrEP, emerging evidence suggests good overall
acceptability among MSM, albeit with significant variance across
countries. A multinational study on oral and parenteral PrEP
found that 92% of MSM in India and 70% in South Africa would
definitely be willing to take PrEP, whilst only 45% of MSM in
Peru would definitely consider taking it [19]. Similarly, 78,5%,
74% and 44% of MSM expressed intentions to take PrEP in three
different studies conducted in the U.S. [20,21,22], and 63%
reported high willingness to use PrEP in a study conducted in
China [23]. Australian MSM have thus far been the most cautious,
with only 28% reporting willingness to use PrEP [24]. Important-
ly, these studies have shed light on country-specific factors likely to
affect PrEP uptake and adherence.
This study examined the attitudes, preferences and future
acceptability of real and hypothetical attributes of PrEP products
among MSM in Thailand. We aimed to inform priority setting,
program design, and product development, should PrEP prove
cost-effective in this context.
Methods
Data Collection
This research was conducted between July 2011 and September
2011 in Bangkok and Chiang Mai. Our study’s methods are
reported in detail elsewhere [19]. In brief, we administered a
questionnaire to MSM to assess their likelihood of adopting PrEP.
Ipsos MORI, a global social research company, coordinated the
data collection and Ipsos Thailand carried out the fieldwork in
consultation with a local NGO working with MSM and
transsexuals. Questionnaire items were discussed with experienced
local researchers and fieldworkers in a focus group setting to check
pertinence and clarity of wording. The questionnaire was
translated in Thai by the local market research team and back-
translated by professional translators in London for content
consistency. The final translation was agreed by consensus.
The protocol of this study was approved by the ethical
committees of Imperial College London and the Institute for the
Development of Human Research Protections, Ministry of Public
Health in Thailand. We obtained informed written consent from
all participants.
Sample
We used targeted sampling [25] _ENREF_9to recruit partic-
ipants and selected different locations to ensure a diverse sample.
These included hairdressing salons, healthcare centers, hotels,
non-governmental organizations (NGOs), nightclubs, red-light
districts, saunas, streets, and universities. HIV prevalence is higher
among MSM and male sex workers than transsexuals [26], thus
MSM were prioritized.
Eligibility was determined using a brief screening interview.
Inclusion criteria were self-identifying as a man who has sex with
men, being 18 years old or older, self-reporting a negative or
unknown HIV serostatus, being sexually active, and not having
taken part in a market research study in the past 12 months.
Participants received an incentive of 500 Baht (US$15) for their
participation.
Measurement
We used a combination of quantitative measures (sections 1–3
and section 5) and conjoint analysis (section 4). The questionnaire
had a total of 57 items in five sections. The first four sections were
interviewer-administered. Section five was self-administered due to
the sensitive nature of the topics [27]. We employed verbal labels
to improve data quality [28]. Unless specified here, we used four-
point Likert scale items (1 = ‘‘yes, definitely’’, 2 = ‘‘yes, probably’’,
3 = ‘‘no, probably not’’, and 4= ‘‘no, definitely not’’) to avoid
midpoints, which can discourage respondents from taking a stand
[29]. However, interviewers were allowed to record spontaneous
‘‘I do not know’’ responses.
Section 1 introduced PrEP as a medication which would reduce
the risk of HIV infection in HIV negative people. A description of
hypothetical and known PrEP attributes, based on the iPrEx
results, expert consultations and a literature review [9,30,31], was
provided. Participants were told that PrEP was: for people who did
not have HIV; that it was ineffective against other sexually
transmitted diseases; that it was being tested as a pill and
eventually as an injection [31]; that clinical tests had shown that
there were 73% fewer HIV infections among MSM who took daily
oral PrEP most of the time – that is to say, at least nine times out of
every ten – [9], that it could cause mild temporary side effects such
as nausea, weight loss and headaches; and that could be partially
protective against HIV, especially if not taken as directed,
therefore frequent HIV tests would be needed. Participants were
encouraged to ask the interviewer to repeat the description if any
part was unclear. Questions about adherence to previous regular
medication regimens were asked towards the beginning of this
section, as a proxy measure for future adherence [32].
Section 2 explored the future acceptability and potential use of
PrEP. We examined participants’ willingness to take PrEP,
likelihood of early adoption, and key attitudes associated with
taking PrEP: embarrassment, anxiety, hope, and fear of contract-
ing HIV.
In section 3, we assessed potential barriers to PrEP use: side
effects, cost (an affordable monthly amount equivalent to two
boxes of headache tablets, as condoms are often free of charge),
willingness to share and sell PrEP if given for free (a limited
amount for personal use), condom use, and HIV testing.
In section 4, we elicited data for conjoint analysis, a statistical
technique frequently used to determine the value people assign to
different features or attributes of products or services [33,34], to
assess the relative importance of key hypothetical and known
attributes of PrEP. By confronting participants with realistic
tradeoff situations, conjoint analysis thus enabled us to test what
combination of PrEP attributes is most critical in participants’
decision making and which attributes are most preferred. Conjoint
analysis was deemed an appropriate and effective means of
exploring participants’ preferences, since PrEP is a new offering
and past observations (data, experience, etc.) are likely to be of
limited help. More specifically, we chose attributes that represent-
ed relevant stages of an implementation program, based on
discussions with academic, policy, and industry experts. Conjoint
analysis was conducted as follows. First, participants were shown a
card with three different PrEP scenarios depicted on it, using both
graphics and text to reduce cognitive effort. Each scenario had a
different combination of five attributes (and corresponding levels):
(1) route of administration (a pill once a day, a pill before and after
having sex, an injection in the arm once a month, or an injection
in the buttocks every two months); (2) dispensing site (pharmacy,
family planning clinic, health clinic, or antiretroviral treatment
clinic); (3) time spent obtaining PrEP (two hours and four hours);
(4) frequency of pick up (every month and every two months); and
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(5) frequency of HIV testing associated with PrEP (monthly or
every six months). Participants then indicated their preferred
choice among the three different PrEP scenarios depicted on each
card, with the option to state that none of the scenarios was
preferable. Each participant responded to ten different cards.
Section 5 collected demographic data, including gender, place
of residence, age, and education, which we used as proxy measure
for socioeconomic status [35]. Participants were then asked to
disclose sensitive information to assess risk behaviors, including
number of sexual partners, type of sex practiced (vaginal and anal),
HIV status, condom, and drug use. Before commencing this
section, participants were reminded about the strict confidentiality
of their responses. Subsequently, they were given a booklet with
pictorial representations of the answers to facilitate comprehension
[36]. We adapted a voting box approach to reduce social
desirability bias [37]_ENREF_32_ENREF_16 and asked partic-
ipants to introduce the filled-out booklet in a blank envelop, seal it,
and place it into a larger envelope containing other sealed
booklets. Booklets had a unique code to link them back to the
interviewer-administered part of the questionnaire.
Statistical Analysis
Conventional descriptive statistics were performed to assess the
characteristics of the study’s participants and their views on PrEP.
Spearman’s rank tests were used to determine correlations
between questionnaire items. Mann-Whitney tests were conducted
to ascertain differences between groups. A p-value less than 0.05
was considered statistically significant. Conjoint analysis was used
to examine the relative importance of key attributes of PrEP. Five
attributes were used to represent PrEP scenarios. To reduce
cognitive effort we combined ‘‘time spent obtaining PrEP’’ and
‘‘frequency of pick up’’, yielding 128 possible scenarios. An
efficient design of 32 scenarios was found and 120 choice tasks
were generated from these 32 scenarios (by combining scenarios
together into sets of three) using SAS 9.3 software. Finally, the 120
choice tasks were split into twelve blocks of ten choice tasks.
Sawtooth CBC/HB Version 50.2.8 software was used to decant
respondents’ choices into respondent-level utilities, using hierar-
chical Bayes estimation, which allowed us to determine the
directionality (positive versus negative) and relative importance of
each level.
Table 1. Participants’ characteristics.
CHARACTERISTIC TOTAL
Gender – n (%)
Male 259 (99)
Transgender 1 (0)
Age group – n (%)
16–18 yr 11 (4)
19–24 yr 139 (54)
25–30 yr 71 (27)
31–35 yr 28 (11)
$36 yr 11 (4)
Education level – n (%)
Less than secondary 2 (1)
Completed secondary 12 (5)
Postsecondary 245 (94)
Rather not say 1 (0)
Experience taking regular medication – n (%)
Having taken regular medication in the past 250 (96)
Not having taken regular medication in the past 9 (4)
Do not know/Cannot remember 1 (0)
HIV testing – n (%)
Having been tested 153 (59)
Not having been tested 107 (41)
Fear of contracting HIV
Very afraid 161 (62)
Fairly afraid 59 (23)
Not very afraid 22 (9)
Not at all afraid 18 (7)
Sexual risk factors – n (%)
Number of partners in the last month
1 partner 108 (42)
2 partners 62 (24)
3–5 partners 37 (14)
$6 partners 13 (6)
Not stated 5 (2)
Frequency of anal sex in the last year*
Several times a week 35 (14)
About once a week 89 (34)
About once a month 65 (25)
Less often than once a month 58 (22)
Not stated 13 (5)
Frequency of vaginal sex in the last year**
Several times a week 0.8 (2)
About once a week 0.4 (1)
About once a month 0.8 (2)
Less often than once a month 5.8 (15)
None of the time 92.3 (240)
Frequency of condom use in the last month
All the time 124 (48)
Most of the time 44 (17)
Some of the time 28 (11)
Table 1. Cont.
CHARACTERISTIC TOTAL
Rarely 7 (3)
None of the time 17 (7)
Not stated 40 (15)
Transactional sex at present
Yes 31 (12)
No 229 (88)
Injecting drug use risk factors – n (%)
Injecting drugs at present
Yes 2 (1)
No 258 (99)
*Anal sex was insertive and/or receptive.
**Vaginal sex reported was bisexual.
Percentages may not total 100 because of rounding.
doi:10.1371/journal.pone.0054288.t001
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Results
Participant Characteristics
We interviewed 260 participants; 130 in Bangkok and 130 in
Chiang Mai. As reported in Table 1, the average respondent was
19–24 years old (54%), reported not having taken regular
medication in the past (96%), was afraid of contracting HIV
(85%), had one sexual partner in the last month (42%), had anal
sex once a week in the past year (34%), and used condoms every
time they had sex in the last year(48%). Most respondents reported
not currently receiving gifts or money for sex (88%) and having
been tested for HIV before (59%). All reported to be HIV
negative.
Future Acceptability and Potential use of PrEP
As reported in Table 2, participants’ willingness to use PrEP
(39.2% ‘‘yes, definitely’’ and 49.2% ‘‘yes, probably’’) and to adopt
it early (22.2% ‘‘yes, definitely’’ and 47.4% ‘‘yes, probably’’) was
high overall. Willingness to use PrEP remained high even after
learning of potential mild side effects (24.6% ‘‘yes, definitely’’ and
56.5% ‘‘yes, probably’’), having to pay 150 Baht/month for it
(58.8% ‘‘yes, definitely’’ and 35.8% ‘‘yes, probably’’), using a
condom in combination with PrEP (52.7% ‘‘yes, definitely’’ and
36.9% ‘‘yes, probably’’), or being regularly tested for HIV (43.6%
‘‘yes, definitely’’ and 44.8% ‘‘yes, probably’’).
We also found that a minority of participants would feel
embarrassed about taking PrEP (2.7% ‘‘very embarrassing’’ and
5.8% ‘‘fairly embarrassing’’) and most would want their partner or
partners to know they were taking it (45.4% ‘‘yes, definitely’’ and
240.2% ‘‘yes, probably’’). However, a considerable minority would
feel anxious about taking PrEP (2.7% ‘‘very anxious’’ and 35.4%
‘‘fairly anxious’’). Participants also reported intentions to share it
(26.5% ‘‘yes, definitely’’ and 43.8% ‘‘yes, probably’’) and sell it to
those who needed it more (6.9% ‘‘yes, definitely’’ and 28.8% ‘‘yes,
probably’’). Yet, most participants felt that PrEP would give them
hope for new possibilities in their lives (38.5% ‘‘a lot of hope’’ and
55.8% ‘‘some hope’’).
Participants’ Characteristics and Likelihood of PrEP Use
As reported in Table 3 and 4, willingness to take PrEP was
positively associated with previous experience taking regular
medication (U= 693, p,0.05, r = 0.16), fear of contracting HIV
(rho= 0.15,0.05), having a greater number of sexual partners in
the last month (rho= 0.13, p,0.05), and more frequent anal sex
(rho= 0.13, p,0.05). Whilst willingness to take PrEP as soon as it
becomes available was negatively associated with frequency of
vaginal sex (rho= -0.16,0.05) and positively associated with
frequency of anal sex (rho= 0.17,0.05). Willingness to take PrEP
despite side effects (rho= 0.16, p,0.05), having to pay (rho= 0.16,
p,0.01) and to use condoms (rho= 0.14, p,0.05) were positively
associated with fear of contracting HIV.
Table 2. Likelihood of PrEP use.
Yes, definitely
(%)
Yes, probably
(%)
No, probably
not (%)
No, definitely
not (%)
Not stated1/Do
not mind2 (%)
If PrEP became available, do you think
you would use it?
39.2 49.2 7.3 4.2
Would you take PrEP as soon as it
becomes available?
19.6 41.9 25.8 1.2 11.51
Would you take PrEP if it caused mild
temporary side effects?
24.6 56.5 13.8 5
Would you take PrEP if you had to pay
500 Baht a month for it?*
58.8 35 4.2 1.9
Would you take PrEP even if you have
to use condoms?
52.7 36.9 8.5 1.9
Do you think you would use PrEP if needed
to be tested regularly for HIV/AIDS?
43.6 44.8 8.1 3.5
Would you want your partner(s)
to know that you are taking PrEP?
45.4 24.2 12.7 11.9 5.82
Would you share PrEP if you only had
enough to protect yourself and was given
for free?
26.5 43.8 12.7 16.9
Would you sell PrEP to other people
who need it more than you?
6.9 28.8 20.4 43.5
Very
embarrassing
Fairly
embarrassing
Not very
embarrassing
Not at all
embarrassing
How embarrassing would you find it to
take PrEP?
2.7 5.8 15 76.5
Very anxious Fairly anxious Not very anxious Not at all anxious
How anxious does the thought of taking
PrEP make you feel?
2.7 35.4 31.9 30
A lot of hope Some hope Not much hope No hope at all
How much hope does PrEP give you? 38.5 55.8 5 0.8
*150 Baht is equal to the cost of two packs of headache medicine in Thailand.
Percentages may not total 100 because of rounding.
doi:10.1371/journal.pone.0054288.t002
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Feeling embarrassed about taking PrEP was negatively associ-
ated number of partners in the last month (rho=20.14, p,0.05),
whereas feeling anxious about taking PrEP was negatively
associated with age (rho=20.13, p,0.05) and frequency of
vaginal sex (rho=20.15, p,0.05), and positively associated with
fear of contracting HIV (rho= 0.15, p,0.05). Those who felt that
PrEP would give them hope were more likely to be afraid of
contracting HIV (rho= 0.22, p,0.01) and to have a greater
number of sexual partners in the last month (rho= 0.13, p,0.05).
Reported intention to share PrEP was negatively correlated with
age (rho=20.13,0.05) and Intention to sell PrEP was negatively
correlated with age (rho=20.15,0.05) and education
(rho=20.17,0.01), and positively correlated with transactional
sex (U= 2508, p,0.01, r = 0.18).
Participants living in Bangkok were more likely to take PrEP as
soon as it becomes available (U= 5639, p,0.05, r = 0.14) and to
pay for PrEP (U=7382, p,0.05, r =220.03), and less likely to sell
PrEP (U= 7382, p,0.05, r = 0.13) than those living in Chiang
Mai.
We found no association between frequency of condom use and
frequency of anal sex in the last year and number of partners in the
last month.
Relative Importance of PrEP Hypothetical Attributes
The frequency of HIV testing was the most important attribute
of a PrEP program, followed by the time it would take to receive
PrEP (Fig. 1). A daily pill was the preferred level of the route of
administration, followed by a monthly injection in the arm. Yet
only 4% of participants reported ever taking regular medication.
The preferred frequency of testing was every six months.
Pharmacies were the favored dispensing site. Frequency of pick
up was not an influential determinant of PrEP use (Fig. 1).
Discussion
Trial results have demonstrated that PrEP can be an effective
prevention method against HIV. Yet PrEP acceptability and users’
ability to adhere to it are likely to have a significant impact on the
success of this new initiative [38].
We examined Thai MSM’s attitudes and preferences towards
PrEP to evaluate its future acceptability among this population.
Our results show that most participants would consider taking
PrEP despite its disadvantages. We found that participants living
in Bangkok were more willing to take PrEP than those living in
Chiang Mai, which may be explained by a more adverse
epidemiological context. Interestingly, when participants were
asked whether they would take PrEP even when having to pay an
affordable amount, using condoms in combination with PrEP or
being regularly tested for HIV, the majority reported they would.
This indicates participants’ motivation to overcome barriers that
can have a significant impact on PrEP uptake. It should not be
inferred that willingness to take PrEP would increase in the
presence of these particular barriers.
Table 3. Correlations between participants’ characteristics and likelihood of PrEP use.
Age Education
Fear of
contracting
HIV
Number of
partners
in the last
month
Frequency of
condom use
in the last
month
Frequency of
vaginal sex
in the last
year
Frequency of
anal sex
in the last
year
If PrEP became available, do you think
you would use it?
0.00 20.02 0.15* 0.13* 0.02 20.07 0.13*
Would you take PrEP as soon as
it becomes available?
0.08 20.05 0.09 0.02 20.09 20.16* 0.17*
Would you take PrEP if it caused
mild temporary side effects?
0.08 20.05 0.16* 0.10 20.02 20.07 0.08
Would you take PrEP if you had
to pay 500 Baht a month for it?*
0.02 0.01 0.16** 0.16* 20.08 20.19** 0.20**
Would you take PrEP even if you have
to use condoms?
20.09 0.04 0.14* 0.11 0.03 0.02 0.10
Do you think you would use PrEP
if needed to be tested regularly
for HIV/AIDS?
20.03 0.05 0.10 20.03 0.04 20.03 0.08
Would you want your partner(s)
to know that you are taking PrEP?
20.06 0.08 0.09 0.04 20.15* 20.01 0.14*
Would you share PrEP if you only
had enough to protect yourself
and was given for free?
20.13* 20.05 0.02 20.05 0.01 0.00 0.04
Would you sell PrEP to other
people who need it more than you?
20.15* 20.17** 0.00 0.10 20.10 20.09 0.04
How embarrassing would you
find it to take PrEP?
0.04 20.02 0.07 20.14* 0.11 20.03 20.06
How anxious does the thought
of taking PrEP make you feel?
20.13* 20.08 0.15* 20.10 0.01 20.15* 20.09
How much hope does PrEP
give you?
0.02 20.08 0.22** 0.13* 20.12 20.07 0.04
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
doi:10.1371/journal.pone.0054288.t003
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We found that participants who took regular medication in the
past, were afraid of contracting HIV and reported having more
partners and more frequent anal sex were also more willing to take
PrEP. Our results also indicate that frequency of condom use was
not associated with sexual risk behaviors. These findings suggest
that those at risk of contracting HIV through sexual contact and
importantly, perceive themselves to be at higher risk, were more
motivated to enroll. Efforts should thus be focused on reaching
these individuals and providing them with adequate information
and access to available HIV prevention methods, including PrEP.
Such efforts should include migrant populations who are currently
not entitled to access public HIV prevention and treatment
services [39].
Worryingly, younger and less educated participants – a proxy
for socioeconomic status [35] –, and those engaging in transac-
tional sex, were more likely to sell PrEP. Enhancing the quality of
the communication between PrEP users and providers, stressing
the risks of poor adherence and implementing relevant monitoring
strategies will therefore be necessary to improve PrEP effectiveness
in this demographic group.
Our results have implications for PrEP eventual demonstration
projects in Thailand. Our data indicate that PrEP could be offered
to MSM at higher risk in the first instance. PrEP should be
affordable and implicit costs such as waiting times should be low.
Delivering PrEP in a confidential and accessible healthcare setting
would be desirable to reduce anxiety. A daily pill and a monthly
injection in the arm would be acceptable routes of administration,
which is encouraging from a policy perspective, as it would allow
both a rapid implementation of existing oral PrEP and the
eventual rollout of parenteral PrEP. The latter may reduce users’
likelihood of sharing, selling or forgetting to take PrEP. In the
meantime, monitoring measures and behavioral interventions
would have to be put in place to ensure adequate levels of
adherence to oral PrEP. Important lessons can be drawn from
successful ART interventions [40,41]. Further research to
understand why the frequency of HIV testing was regarded as
the most important PrEP attribute is needed to prevent it from
becoming a barrier to implementation.
Reassuringly, the characteristics of our sample compare well to
those of larger studies among MSM in Thailand [42,43], making it
more likely that the views of the participants of our study are
representative of the assessed population. PrEP acceptability levels
among Thai MSM resonate with those reported in previous
research [20,21,23], yet drawing comparisons with these studies
Table 4. Differences between participants’ characteristics and likelihood of PrEP use.
City of residence
Experience taking regular
medication HIV testing Transactional sex at present
MD MD MD MD MD MD MD MD
B C U r Yes No U r Yes No U R Yes No U r
Willingness to
take PrEP
3 3 7815 0.07 3 3 693 0.16* 3 3 7511 0.08 4 3 3103 0.08
As soon as it
becomes
available
3 3 5639 0.14* 3.5 3 463 0.09 3 3 6051 0.06 3 3 2482 0.09
Despite side
effects
3 3 7879 0.07 4 3 1194 0.02 3 3 7643 0.06 3 3 3061 0.09
Despite having
to pay
4 4 7382 0.13* 4 4 1114 0.04 4 4 8098 0.01 4 4 3091 0.08
Despite having
to use condoms
4 4 8227 0.03 4 3.5 1042 0.06 4 4 8075 0.01 4 4 2926 0.11
Despite being
tested regularly
for HIV
3 3 8231 0.02 3.5 3 908 0.10 3 3 7605 0.07 4 3 2527 0.18**
Would you share
PrEP
3 3 8376 0.01 3 3 1063 0.05 3 3 7979 0.02 3 3 3309 0.04
Would you sell
PrEP
2 1 7149 0.14* 1 2 903 0.03 2 2 7411 0.09 3 2 2508 0.18**
Would want
partner(s) to
know
4 4 8019 0.05 4.5 4 1035 0.15* 4 4 7263 0.10 4 4 2917 0.11
Would find
taking PrEP
embarrassing
1 1 8385 0.01 1 1 1059 0.07 1 1 7751 0.06 1 1 3491 0.01
Would you feel
anxious about
taking PrEP
2 2 8417 0.00 2.5 2 1091 0.04 2 2 7421 0.08 2 2 3102 0.07
Would taking
PrEP give you
hope
3 3 8360 0.01 4 3 1017 0.07 3 3 8179 0.00 4 3 2986 0.10
**Difference is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed).
MD: median. U: Mann Whitney’s U-statistic. r: effect size estimate (r= Z/!N; N =number of observations). B: Bangkok; C: Chiang Mai.
doi:10.1371/journal.pone.0054288.t004
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should be done with caution, as their methods differ greatly.
Notably, Indian, South African and, to a lesser extent, Peruvian
MSM reported willingness to use PrEP in an analogous study
conducted by our team before the publication of the iPrEx results
on the acceptability of mostly uncertain PrEP attributes [19]. This
may indicate that the acceptability of a more realistic PrEP may be
comparable to that of a largely hypothetical one. However, the
same study shows that most MSM preferred parenteral PrEP,
whereas Thai MSM preferred daily oral PrEP. This suggests that
an existing but less convenient PrEP regimen may be preferred to
a less demanding but hypothetical one. It may also indicate that
Thai MSM may be overestimating their capacity to adhere to oral
PrEP, as most participants reported not having experienced taking
regular medication in the past.
There are some limitations to this study. Given the sensitive
nature of the addressed questions, some participants may have felt
at times inclined to provide what they felt was the ‘‘right’’ answer.
Additionally, our data collection took place in urban areas, where
HIV incidence is normally higher, thus current findings may not
be generalizable to rural settings. Finally, examining acceptability
among users enrolled in demonstration projects is much deserving,
as actual acceptability may differ from potential willingness to take
PrEP.
Our results offer valuable insights that can help to deliver PrEP
more effectively, should Thailand decide to implement it, by
focusing their efforts on the most critical aspects of its implemen-
tation. Importantly, offering combination prevention packages
which encompass both behavioral and biomedical HIV prevention
methods, depending on individual circumstances and needs, will
be essential to control the spread of HIV [44]. Communicating
PrEP benefits and disadvantages in an unbiased and concise
manner and involving key community representatives in PrEP
implementation process will help to reduce potential apprehen-
sions among stakeholders, facilitate PrEP introduction and
increase uptake [45]. Yet, tackling stigma and healthcare
inequalities will be necessary for existing and new prevention
methods to significantly decrease HIV incidence among high-risk
populations.
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